DEI BioPharma completed the acquisition of a 51% stake in Neocell Bio-Technologies.

DEI BioPharma, a producer of medicines and vaccines, completed the acquisition of a 51% stake in Neocell Bio-Technologies, a provider of contract research, development, and technology transfer services for biologics and biosimilars. Financial terms were not disclosed.